People · Operator
Named in public records as an officer, director or promoter · active 2014–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Compound Holdings I, LLC | — | Pharmaceuticals | Growth/Late | $412.0M | $15.0B | 2014 |
| DBV Technologies S.A. | — | Pharmaceuticals | Series D+ | $306.9M | $2.6B | 2025 |
| Alcresta Therapeutics, Inc. | — | Biotechnology | Series C | $75.9M | $409.6M | 2016 |
| Bellerophon Therapeutics, Inc. | — | Pharmaceuticals | Series B | $25.0M | $796.9M | 2017 |
Daniel Tasse at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel Tasse on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| William Scheinler | 2 | 2 |
| Timothy Sullivan | 1 | 16 |
| Garheng Kong | 1 | 16 |
| James Topper | 1 | 12 |
| ADAM WEINSTEIN | 1 | 11 |
| Stephen Kraus | 1 | 7 |
| ANDRE MOURA | 1 | 6 |
| Nicholas Alexos | 1 | 6 |
| Parag Shah | 1 | 4 |
| Jonathan M Peacock | 1 | 4 |
| Todd Creech | 1 | 4 |
| MATTHEW HOLT | 1 | 4 |
| Andre V. Moura | 1 | 3 |
| Alexey Margolin | 1 | 3 |
| MATTHEW BENNETT | 1 | 2 |
| Stephen Ross | 1 | 2 |
| Pharis Mohideen | 1 | 2 |
| Julie O'Neill | 1 | 2 |
| Mailys Ferrere | 1 | 2 |
| Robert Gallotto | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.